Use of Pulsatile Intravenous FSH to Mitigate Reprometabolic Syndrome — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Use of Pulsatile Intravenous FSH to Mitigate Reprometabolic Syndrome — Stella

Recruiting

Back to Infertility trials

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

United States

University of Colorado Anschutz Medical Campus, Aurora, Colorado

Key details

Phase

Early testing

Sponsor

University of Colorado, Denver

Enrollment target

~5 participants

Started

October 2024

Primary completion

November 2025

This trial's estimated completion date has passed — the record may not be fully up to date.

Age range

19 Years – 37 Years

Sex

Female only

Last updated November 2024

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov